Royal Bank Of Canada restated their outperform rating on shares of Shire PLC (LON:SHP) in a research note issued to investors on Friday morning.
Other equities research analysts have also recently issued reports about the stock. Beaufort Securities reissued a long term buy rating and set a GBX 4,900 ($64.45) price target (down from GBX 6,200 ($81.55)) on shares of Shire PLC in a research report on Friday, August 4th. Shore Capital reissued a buy rating on shares of Shire PLC in a research report on Monday, November 13th. cut their price target on shares of Shire PLC from GBX 4,480 ($58.92) to GBX 4,050 ($53.27) and set a hold rating on the stock in a research report on Tuesday, October 31st. Citigroup Inc. reissued a buy rating and set a GBX 6,300 ($82.86) price target on shares of Shire PLC in a research report on Tuesday, August 22nd. Finally, Jefferies Group LLC cut their price target on shares of Shire PLC from GBX 5,600 ($73.66) to GBX 5,250 ($69.05) and set a buy rating on the stock in a research report on Monday, August 7th. Four equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the company’s stock. Shire PLC has a consensus rating of Buy and an average price target of GBX 5,358.82 ($70.48).
Shares of Shire PLC (SHP) traded down GBX 65.50 ($0.86) during midday trading on Friday, reaching GBX 3,678.50 ($48.38). 5,224,379 shares of the company were exchanged, compared to its average volume of 2,540,000. Shire PLC has a 12-month low of GBX 3,435.50 ($45.19) and a 12-month high of GBX 5,067 ($66.64).
TRADEMARK VIOLATION WARNING: This piece of content was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece of content on another domain, it was illegally stolen and republished in violation of U.S. & international copyright and trademark laws. The legal version of this piece of content can be accessed at https://www.dispatchtribunal.com/2017/11/18/shire-plcs-shp-outperform-rating-reaffirmed-at-royal-bank-of-canada.html.
In related news, insider Flemming Ornskov purchased 8,400 shares of the firm’s stock in a transaction that occurred on Tuesday, August 22nd. The shares were acquired at an average price of GBX 3,665 ($48.20) per share, for a total transaction of £307,860 ($404,919.11). Also, insider Anne Minto purchased 190 shares of the firm’s stock in a transaction that occurred on Friday, September 29th. The stock was bought at an average price of GBX 3,785 ($49.78) per share, for a total transaction of £7,191.50 ($9,458.77).
About Shire PLC
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.